Part 3/Chapter 13/8-min read

Vascular Infection, Graft/Endograft Infection, Infected Aneurysm, and Aortoenteric Fistula

Vascular and prosthetic graft infection, infected aneurysm, and aortoenteric fistula approached as overlapping clinical syndromes rather than as a single naming problem. The chapter frames suspicion, classification, source control, conduit choice, and antimicrobial duration so each syndrome gets its appropriate operation.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·6 sections · 38 references

Listen to this chapter8 min · AI audio edition · two hostsAI narration

Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.

General medical education, not patient-specific advice.

Choose the hosts

Definition and presentation

Vascular graft infection, mycotic (infected) native aneurysm, and endovascular infection constitute a single multidisciplinary management domain encompassing prosthetic material, the native arterial wall, adjacent bowel, and overlying soft tissue . Standardized terminology dictates consistent classification across surgical, infectious disease, and imaging disciplines .

Endograft infection is uncommon but carries substantial early mortality and is frequently delayed. Following endovascular aneurysm repair (EVAR), the incidence of endograft infection is approximately 0.6%, with a mean interval to diagnosis of 22 to 25 months; more than one quarter of presentations involve an aortic fistula . Surveillance encounters late after EVAR or thoracic endovascular aortic repair (TEVAR) require evaluation of new constitutional symptoms, unexplained inflammation, perigraft gas or fluid, or bleeding to differentiate infection from routine aneurysm evolution.

Diagnosis uses the Management of Aortic Graft Infection Collaboration (MAGIC) criteria, integrating clinical, surgical, microbiologic, and imaging inputs. The MAGIC framework serves as a sensitive screen; treating all suspected cases as infected yields sensitivity between 88.2% and 99%, but specificity relies on careful correlation to avoid premature explantation in low-probability scenarios .

DiagnosticMAGIC diagnostic classification criteria
Adult with prior reconstruction
Diagnostic trigger
A single major criterion or two minor criteria from different categories
Diagnostic classification
Suspected infection
Citation
Adult with prior reconstruction
Diagnostic trigger
One major criterion plus any additional criterion
Diagnostic classification
Diagnosed infection
Citation

Microbiology and diagnostic imaging

Appropriate empirical antimicrobial therapy independently predicts survival in hospitalized patients with vascular graft infection . Empiric therapy is anchored to the anatomic site and expected flora. For abdominal disease without aortoenteric fistula, the intended empiric spectrum covers gram-positive cocci, gram-negative bacilli, and anaerobes, with narrowing once operative cultures identify the target organism . In practice this means vancomycin (or daptomycin or linezolid) for MRSA and gram-positive cover plus an antipseudomonal beta-lactam such as piperacillin-tazobactam or a carbapenem for gram-negative and anaerobic cover; add an echinocandin or other antifungal when Candida graft infection is plausible, as with aortoenteric fistula, prior broad-spectrum antibiotics, or immunosuppression .

Pathogen identity shapes both prognosis and diagnostic suspicion. Candida aortic graft infection establishes a distinct organism category with different counseling implications from non-Candida infection . Fastidious organisms such as Actinomyces require targeted deep cultures and adjustment of antimicrobial assumptions when the clinical course diverges from typical bacterial infection .

Imaging defines perigraft infection, fluid collections, bowel involvement, and the feasibility of reconstruction. Computed tomography angiography (CTA) maps the operative field but provides modest pooled diagnostic sensitivity (0.67) and specificity (0.63) for vascular graft infection; metabolic and nuclear imaging resolve ambiguity when CTA is equivocal . For patients under late endograft surveillance, structural correlation with focal or heterogeneous uptake is required before committing to reoperation, rather than relying on a single maximum standardized uptake value (SUVmax) threshold . Quantitative baseline characteristics and FDG-PET imaging metrics do not reliably predict in-hospital or longer-term survival .

DiagnosticDiagnostic imaging performance in vascular graft infection
  • CTA
    Indication and utility
    Anatomic mapping and baseline assessment
    Diagnostic performance and pitfalls
    Modest pooled sensitivity (0.67) and specificity (0.63)
    Citation
  • 18F-FDG PET/CT
    Indication and utility
    Equivocal CT findings or localizing infection prior to reoperation
    Diagnostic performance and pitfalls
    Sensitivity 0.92 to 0.95, specificity 0.76 to 0.80; false positives occur from persistent early postoperative inflammation
    Citation
  • White-cell SPECT/CT
    Indication and utility
    Equivocal CT findings
    Diagnostic performance and pitfalls
    High sensitivity (0.99) and specificity (0.82)
    Citation

Treatment and reconstruction thresholds

Antimicrobial therapy reduces microbial burden and treats bacteremia, but operative source control is required to remove infected prosthetic material, close fistulas, and debride necrotic tissue . Complete excision of infected material with in-situ reconstruction is the standard for patients who can tolerate the physiological burden. Emergency operative timing is an independent predictor of early mortality, prioritizing preoperative physiologic stabilization when feasible .

In-situ reconstruction incorporates aggressive debridement, targeted conduit selection, prolonged antibiotic therapy, and vascularized tissue coverage; omental coverage specifically improves infection clearance and healing . Conduit choices include autogenous femoral vein (neoaortoiliac system, NAIS), cryopreserved allograft, antibiotic-bonded prosthetic, and silver-impregnated prosthetic. NAIS and cryopreserved allografts show no statistically significant difference in 30-day or 1-year mortality for fit patients, though overall morbidity remains high (81%) and recurrent sepsis frequently involves gram-negative and drug-resistant organisms . Peripheral prosthetic infections use the same source-control and follow-up principles .

DiagnosticAbdominal aortic graft infection surgical strategies
  • Fit patient with safely resectable infection
    Preferred management pathway
    Complete graft removal and in-situ reconstruction
    Outcomes and key caveats
    Lowest reinfection rate (8%) and superior 3- to 5-year survival compared to extra-anatomic bypass (reinfection 22.4%)
    Citation
  • Localized contamination, intact anastomoses, no bowel communication
    Preferred management pathway
    Graft preservation with debridement
    Outcomes and key caveats
    Requires prolonged antibiotic stewardship; 1-year mortality (16.1% vs 28.7% for removal) is confounded by strict patient selection
    Citation
  • Prohibitive operative risk or unfit for excision
    Preferred management pathway
    Percutaneous drainage and suppressive antibiotics
    Outcomes and key caveats
    Palliative strategy; in-hospital mortality reaches 63.3%; retained infected material drives persistent sepsis risk
    Citation

The operative decision pathway follows a stepwise assessment of fitness, contamination, and source-control feasibility:

  1. Baseline operative risk and the feasibility of definitive source control dictate the management pathway.
  2. Complete graft excision and in-situ reconstruction (autogenous vein, cryopreserved allograft, or antimicrobial-bonded prosthetic) or extra-anatomic bypass is the standard of care for fit patients with resectable disease.
  3. Partial excision or graft preservation with aggressive debridement is reserved for highly selected patients with localized contamination, intact anastomoses, and no fistula, requiring long-term antibiotic commitment.
  4. Suppressive antimicrobial therapy and percutaneous drainage constitute palliative management for prohibitive operative risk, reflecting the reality that retained infected material drives future sepsis.

Aortoenteric fistula and infected native aneurysm

Aortoenteric fistula presents as a hemorrhage and sepsis emergency. Definitive management for secondary aortoenteric fistula is surgical, consisting of complete graft excision combined with either extra-anatomic bypass or in-situ reconstruction and concurrent broad-spectrum antibiotics . Endovascular repair provides high initial hemodynamic stabilization (approximately 86% in primary fistula) but is followed by a downstream rebleeding or reinfection rate near 42% to 44%, requiring conversion to open repair in up to one-third of patients . Preoperative sepsis and a secondary fistula etiology predict worse outcomes. Endovascular therapy is therefore used as a temporizing bridge in unstable patients, not as definitive source control .

Infected native aortic aneurysms demand a similar distinction between temporization and definitive therapy. Open surgical repair is associated with a lower rate of subsequent graft infection compared to endovascular exclusion (5.4% versus 13.3%), although selection bias heavily favors open repair in fitter patients . Endovascular exclusion serves as a hemorrhage-control or bridging strategy in high-risk patients; it carries a hospital mortality of 11.8%, 1- and 2-year cumulative survival of 86.3% and 80.5%, and a recurrent aortic infection rate of 23.3%, mandating lifelong antibiotics and structured surveillance .

Postoperative surveillance and antimicrobial suppression

The chosen operative or endovascular strategy determines the postoperative surveillance burden and expected failure modes. Long-term incidence of vascular graft infection is similar following open abdominal aortic aneurysm repair and EVAR, and late mortality remains substantial when infected grafts are not explanted .

Post-treatment surveillance tracks constitutional symptoms, inflammatory markers, operative cultures, perigraft collections, and metabolic imaging trajectory. Anticipated failure modes dictate imaging intervals: endovascular bridges and graft-preservation strategies require monitoring for progressive infection and new fistulization, while in-situ reconstructions require monitoring for reinfection, pseudoaneurysm, and progressive conduit degeneration .

Antimicrobial suppression constitutes active longitudinal therapy. Treatment duration and operative-culture narrowing are guided by multispecialty consensus . After complete graft excision with reconstruction, give a minimum of 4 to 6 weeks of organism-directed parenteral antibiotics . When infected prosthetic material is retained or an in-situ prosthetic conduit is placed in an infected field, add lifelong oral suppressive therapy. Outpatient parenteral antimicrobial therapy (OPAT) for aortic vascular graft infection introduces substantial treatment intensity and line-related events after hospital discharge, requiring continuous reassessment of the reconstructive plan in response to recurrent sepsis or toxicity .

Areas of controversy

The prognostic utility of quantitative metabolic imaging metrics (such as SUVmax cutoffs on 18F-FDG PET/CT) is unestablished for reliably predicting in-hospital mortality, long-term survival, or definitive operative timing in vascular graft infection .

The comparative durability and equivalence among in-situ reconstruction conduits (autogenous vein, cryopreserved allograft, silver-impregnated prosthetics, and antibiotic-bonded prosthetics) remain heavily confounded by selection bias, with broadly similar pooled reinfection rates but differing availability and operative burdens .

The long-term safety of partial graft excision or graft preservation for localized contamination lacks randomized validation; reported survival advantages in small cohorts are recognized as reflections of stringent patient selection rather than equivalence of indication .

References

  1. 1.
    Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association. Circulation. 2016.
    PubMed-indexed articleClinical practice guideline2016

    Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association. Circulation. 2016. doi:10.1161/cir.0000000000000457.

    PubMedDOI
  2. 2.
    Vascular Graft and Endograft Infections: A Delphi Consensus Document on Terminology, Definitions, Treatment, Outcomes, Follow Up, and Reporting Standards. 2026.
    PubMed-indexed articleClinical practice guideline2026

    Vascular Graft and Endograft Infections: A Delphi Consensus Document on Terminology, Definitions, Treatment, Outcomes, Follow Up, and Reporting Standards. 2026. doi:10.1016/j.ejvs.2025.07.044.

    PubMedDOI
  3. 3.
    Endograft Infection After Endovascular Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-analysis. Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists. 2017.
    PubMed-indexed articleMeta-analysis / systematic review2017

    Endograft Infection After Endovascular Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-analysis. Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists. 2017. doi:10.1177/1526602817722018.

    PubMedDOI
  4. 4.
    Treatment and outcomes of aortic endograft infection. Journal of vascular surgery. 2016.
    PubMed-indexed articleRegistry / cohort2016

    Treatment and outcomes of aortic endograft infection. Journal of vascular surgery. 2016. doi:10.1016/j.jvs.2015.08.113.

    PubMedDOI
  5. 5.
    European Society for Vascular Surgery 2020 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections. 2020.
    PubMed-indexed articleClinical practice guideline2020

    European Society for Vascular Surgery 2020 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections. 2020. doi:10.1016/j.ejvs.2019.10.016.

    PubMedDOI
  6. 6.
    Validation of the MAGIC Criteria for the Diagnosis of Vascular Graft/Endograft Infection. 2021.
    PubMed-indexed article2021

    Validation of the MAGIC Criteria for the Diagnosis of Vascular Graft/Endograft Infection. 2021. doi:10.1016/j.ejvs.2021.05.010.

    PubMedDOI
  7. 7.
    Diagnosis of prosthetic vascular graft infection using the management aortic graft infection collaboration (MAGIC) criteria. Vascular. 2026.
    PubMed-indexed article2026

    Diagnosis of prosthetic vascular graft infection using the management aortic graft infection collaboration (MAGIC) criteria. Vascular. 2026. doi:10.1177/17085381251326995.

    PubMedDOI
  8. 8.
    Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study. Open forum infectious diseases. 2022.
    PubMed-indexed articleRegistry / cohort2022

    Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study. Open forum infectious diseases. 2022. doi:10.1093/ofid/ofac054.

    PubMedDOI
  9. 9.
    Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2025.
    PubMed-indexed articleClinical practice guideline2025

    Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2025. doi:10.1016/j.cmi.2025.07.020.

    PubMedDOI
  10. 10.
    Outcomes of Candida and Non-Candida Aortic Graft Infection. Vascular and endovascular surgery. 2023.
    PubMed-indexed article2023

    Outcomes of Candida and Non-Candida Aortic Graft Infection. Vascular and endovascular surgery. 2023. doi:10.1177/15385744221129236.

    PubMedDOI
  11. 11.
    Actinomyces spp. Prosthetic Vascular Graft Infection (PVGI): A Multicenter Case-Series and Narrative Review of the Literature. Microorganisms. 2023.
    PubMed-indexed article2023

    Actinomyces spp. Prosthetic Vascular Graft Infection (PVGI): A Multicenter Case-Series and Narrative Review of the Literature. Microorganisms. 2023. doi:10.3390/microorganisms11122931.

    PubMedDOI
  12. 12.
    Diagnostic Imaging in Vascular Graft Infection: A Systematic Review and Meta-Analysis. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. 2018.
    PubMed-indexed articleMeta-analysis / systematic review2018

    Diagnostic Imaging in Vascular Graft Infection: A Systematic Review and Meta-Analysis. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. 2018. doi:10.1016/j.ejvs.2018.07.010.

    PubMedDOI
  13. 13.
    [(18)F] FDG PET/CT can improve the diagnostic accuracy for aortic endograft infection. Acta cardiologica. 2022.
    PubMed-indexed article2022

    [(18)F] FDG PET/CT can improve the diagnostic accuracy for aortic endograft infection. Acta cardiologica. 2022. doi:10.1080/00015385.2021.1949105.

    PubMedDOI
  14. 14.
    The value of 18F-FDG-PET-CT in the management of infective native aortic aneurysms. Vascular. 2021.
    PubMed-indexed article2021

    The value of 18F-FDG-PET-CT in the management of infective native aortic aneurysms. Vascular. 2021. doi:10.1177/1708538120987971.

    PubMedDOI
  15. 15.
    Aortic Vascular Graft and Endograft Infection - Patient Outcome Cannot Be Determined Based on Pre-Operative Characteristics DOI: 10.3390/jcm13010269
    PubMed-indexed articleRegistry / cohort2024
    PubMedDOIOpen PDF
  16. 16.
    Prosthetic vascular graft infection: A systematic review and meta-analysis on diagnostic accuracy of 18FDG PET/CT. General thoracic and cardiovascular surgery. 2022.
    PubMed-indexed articleMeta-analysis / systematic review2022

    Prosthetic vascular graft infection: A systematic review and meta-analysis on diagnostic accuracy of 18FDG PET/CT. General thoracic and cardiovascular surgery. 2022. doi:10.1007/s11748-021-01682-6.

    PubMedDOI
  17. 17.
    Management and Clinical Outcome of Aortic Graft Infections: A Single-Center Retrospective Study DOI: 10.3390/jcm11216588
    PubMed-indexed articleRegistry / cohort2022
    PubMedDOIOpen PDF
  18. 18.
    Infections of the aorta DOI: 10.1007/s12055-021-01173-6
    PubMed-indexed articleReview2022
    PubMedDOIOpen PDF
  19. 19.
    Neoaortoiliac system and cryopreserved human allograft for the treatment of aortic graft infections DOI: 10.1177/17085381221091372
    PubMed-indexed articleRegistry / cohort2023
    PubMedDOIOpen PDF
  20. 20.
    Outcomes Following in Situ Reconstruction for Aortic Infection with the Neo-Aortoiliac System and Aortic Homograft. Annals of vascular surgery. 2023.
    PubMed-indexed article2023

    Outcomes Following in Situ Reconstruction for Aortic Infection with the Neo-Aortoiliac System and Aortic Homograft. Annals of vascular surgery. 2023. doi:10.1016/j.avsg.2022.10.006.

    PubMedDOI
  21. 21.
    Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. 2014.
    PubMed-indexed articleClinical practice guideline2014

    Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. 2014. doi:10.1093/cid/ciu444.

    PubMedDOI
  22. 22.
    Peripheral Prosthetic Vascular Graft Infection: A 5-Year Retrospective Study DOI: 10.3390/medsci13020071
    PubMed-indexed articleRegistry / cohort2025
    PubMedDOIOpen PDF
  23. 23.
    Surgical management of abdominal aortic graft infection: network meta-analysis. BJS open. 2024.
    PubMed-indexed articleMeta-analysis / systematic review2024

    Surgical management of abdominal aortic graft infection: network meta-analysis. BJS open. 2024. doi:10.1093/bjsopen/zrad151.

    PubMedDOI
  24. 24.
    Clinical outcome of graft removal versus preservation in abdominal aortic graft infection: a systematic review and meta-analysis. Annals of surgical treatment and research. 2023.
    PubMed-indexed articleMeta-analysis / systematic review2023

    Clinical outcome of graft removal versus preservation in abdominal aortic graft infection: a systematic review and meta-analysis. Annals of surgical treatment and research. 2023. doi:10.4174/astr.2023.105.4.207.

    PubMedDOI
  25. 25.
    Percutaneous Drainage for Aortic Graft Infection Post-aneurysm Repair: A Viable Option? Vascular and endovascular surgery. 2022.
    PubMed-indexed article2022

    Percutaneous Drainage for Aortic Graft Infection Post-aneurysm Repair: A Viable Option? Vascular and endovascular surgery. 2022. doi:10.1177/15385744221075136.

    PubMedDOI
  26. 26.
    Outcomes of conservative treatment for thoracic vascular graft infections DOI: 10.1093/ejcts/ezaf171
    PubMed-indexed articleRegistry / cohort2025
    PubMedDOIOpen PDF
  27. 27.
    Secondary aortoenteric fistula: surgeon's narrative review DOI: 10.5114/amsad/186358
    PubMed-indexed articleReview2024
    PubMedDOIOpen PDF
  28. 28.
    A Case Series of Secondary Aortoenteric Fistula after Open Aortic Aneurysm Repair: Timing and Technique of Surgery DOI: 10.3400/avd.cr.22-00031
    PubMed-indexed articleCase report2022
    PubMedDOIOpen PDF
  29. 29.
    In situ reconstruction with autologous graft in the treatment of secondary aortoenteric fistulas: A retrospective case series DOI: 10.1016/j.amsu.2019.11.020
    PubMed-indexed article2019
    PubMedDOIOpen PDF
  30. 30.
    Primary aortoenteric fistula: endovascular repair review DOI: 10.5114/kitp.2022.122092
    PubMed-indexed articleReview2022
    PubMedDOIOpen PDF
  31. 31.
    Outcome after endovascular stent graft repair of aortoenteric fistula: A systematic review. Journal of vascular surgery. 2009.
    PubMed-indexed articleMeta-analysis / systematic review2009

    Outcome after endovascular stent graft repair of aortoenteric fistula: A systematic review. Journal of vascular surgery. 2009. doi:10.1016/j.jvs.2008.08.068.

    PubMedDOI
  32. 32.
    Secondary aortoenteric fistula after endovascular aortic interventions: a systematic literature review. Journal of vascular and interventional radiology: JVIR. 2008.
    PubMed-indexed articleMeta-analysis / systematic review2008

    Secondary aortoenteric fistula after endovascular aortic interventions: a systematic literature review. Journal of vascular and interventional radiology: JVIR. 2008. doi:10.1016/j.jvir.2007.10.013.

    PubMedDOI
  33. 33.
    Analysis of antibiotic strategies to prevent vascular graft or endograft infection after surgical treatment for infective native aortic aneurysms: a systematic review. Antimicrobial resistance and infection control. 2024.
    PubMed-indexed articleMeta-analysis / systematic review2024

    Analysis of antibiotic strategies to prevent vascular graft or endograft infection after surgical treatment for infective native aortic aneurysms: a systematic review. Antimicrobial resistance and infection control. 2024. doi:10.1186/s13756-024-01477-3.

    PubMedDOI
  34. 34.
    Midterm outcomes of endovascular treatment for infected aortic aneurysms: Single center experience. Vascular. 2024.
    PubMed-indexed article2024

    Midterm outcomes of endovascular treatment for infected aortic aneurysms: Single center experience. Vascular. 2024. doi:10.1177/17085381221140170.

    PubMedDOI
  35. 35.
    Vascular Graft Infection After Aneurysm Repair: A Population-Based Study. Mayo Clinic proceedings. 2023.
    PubMed-indexed articleRegistry / cohort2023

    Vascular Graft Infection After Aneurysm Repair: A Population-Based Study. Mayo Clinic proceedings. 2023. doi:10.1016/j.mayocp.2023.02.027.

    PubMedDOI
  36. 36.
    Outpatient parenteral antimicrobial therapy (OPAT) for aortic vascular graft infection; a five-year retrospective evaluation DOI: 10.1186/s12879-021-06373-4
    PubMed-indexed articleRegistry / cohort2021
    PubMedDOIOpen PDF
  37. 37.
    Aortic Endograft Infection: Diagnosis and Management DOI: 10.5758/vsi.230071
    PubMed-indexed articleReview2023
    PubMedDOIOpen PDF
  38. 38.
    A Meta-Analysis of Outcomes After In Situ Reconstructions for Aortic Graft Infection. Angiology. 2018.
    PubMed-indexed articleMeta-analysis / systematic review2018

    A Meta-Analysis of Outcomes After In Situ Reconstructions for Aortic Graft Infection. Angiology. 2018. doi:10.1177/0003319717710114.

    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions